Bleomycetin antitumor activity in relation to solid mouse tumors

The antitumor activity of bleomycetin or bleomycin A5 was studied with respect to sarcoma 180, Garding-Passey melanoma, cervical carcinoma CC-5 and lymphosarcoma L10-1. Bleomycetin showed a high selective effect on the solid form of sarcoma 180. Its activity against Garding-Passeys melanoma and cerv...

Full description

Saved in:
Bibliographic Details
Published inAntibiotiki Vol. 26; no. 9; p. 694
Main Authors Bazhanov, V S, Shorin, V A
Format Journal Article
LanguageRussian
Published Russia (Federation) 01.09.1981
Subjects
Animals
Bleomycin - therapeutic use
Drug Evaluation, Preclinical
Female
Lymphoma, Non-Hodgkin - drug therapy
Male
Melanoma - drug therapy
Mice
Mice, Inbred C3H
Mice, Inbred CBA
Neoplasm Transplantation
Neoplasms, Experimental - drug therapy
Sarcoma 180 - drug therapy
Uterine Cervical Neoplasms - drug therapy
Online AccessGet more information

Cover

More Information
Summary:The antitumor activity of bleomycetin or bleomycin A5 was studied with respect to sarcoma 180, Garding-Passey melanoma, cervical carcinoma CC-5 and lymphosarcoma L10-1. Bleomycetin showed a high selective effect on the solid form of sarcoma 180. Its activity against Garding-Passeys melanoma and cervical carcinoma CC-5 was lower. Lymphosarcoma L10-1 was most resistant to bleomycetin. The intravenous route of bleomycin administration had no advantages over subcutaneous administration of the antibiotic.
ISSN:0003-5637